growth. headwinds and hope thank to that joining is the delivering well. morning, very Good team a our we and of our guidance, face this the with I our am quarter, able negative call. I business positive you Despite everyone pleased to its our minimize quarter colleagues our impacts. were XXXX of business exceed challenge QX this Thank and earnings you, for year-on-year COVID-XX Nate. to and everyone to the management second adaptability resilience posed
As signs call, in are impacts we our the will the seeing revenues. stemming on color an to from and we on and to turn into did to some quarter the performance our of business our start backlog recovery I’ll ability first growing earnings profitable future, we virus. our giving the the positive update impacts QX then on convert with provide our
operating the to guidance, of difficult out. COVID-XX the amidst with further Regarding particular, you more fluid go in makes guide precision, environment nature the it
on quantitative providing call. only are we third the reason, this quarter For today’s for guidance
QX, QX. which as QX adjusted will to expand improve upon However, rates higher EBITDA higher growth we same his months, for continue year-on-year Chris similar last should the we than they remarks, guiding or that be be in at have expect several revenue metrics key the over to to and than are operating pace
take second the depth. little Let’s a look quarter in at a more
call results, at like quarter highlights. prior would results second above out year-on-year growth. quarter reflecting positive I or Second year to were three
billion, First, growth. net $X.XX year-on-year authorizations XX.X% reached representing
X.XXx. book-to-bill net was Our
experienced we activity unusual related no addition, In cancellation COVID-XX. to
performance of year-on-year. And revenue that which in segment, we operational is backlog XX.X% noting challenges. conversion also lab billion notably a It $X.X nearly XX.X% we worth revenue strong record, our COVID-XX of backlog ending growth rate despite is third, a with XXX relatively growth achieved achieved positive growth new year-on-year and achieved representing of our EBITDA XX%. Second, strong
seizing the it brought The complexities opportunities all are support navigating and to PPD, pandemic successfully opportunities and for with we customers. our the and challenges quarter posed second by
priorities strength; few patient financial provide part and Chris upon and remarks. third, safety; Our since on Bill these business of maintaining being second, remained summary of consistent expand comments which continuity employee will COVID-XX. beginning and a I first, and priorities, the pandemic: in the will the have their solution to
First, priority and be has patient safety. our top to and continues colleague
We thoughtful reopening take a to office resumption approach of continue to travel. and
implementation We erring more medical and our we of our may the to is on not just procedures own caution. regulations second or important be the business put, safety than views but continuity. are using side judgment Simply priority, to are of guidance local where experts. of permissive internal Successful also our policies
labs full capacity our experienced has practices us we the operate of that all labs. of allowed to has For driver been continue in the key to example, performance a across teams have QX. the adopted, near revised lab’s at This
Let’s our go second priority, continuity. a business deeper into little
teams to off are kicking and studies a While seeing effectively studies lessening are continuing, impacts ongoing we from continue see our gradual conditions, the progressing new majority local the COVID-XX, we of and impacts. Notably, ever-changing are work. despite of
credit nearly we instance, activated of year to of in For as as XXXX. sites in success June three many our I did strengths fundamental June we this successfully of PPD.
the which footprint, to team alternate globe, regions in COVID-XX; the causal enabling by implementation been whose us down posed of to allows of strategies. conversion up flex backlog our are data and impacted our enabling experience the fast strategies our customers third, keep networks, and management strong studies running; offers are as their site global technology our rate and to tenure mitigating across second, also despite and impediments recent and adaptability continue in relatively have First, investments
quarter In of acceleration studies digital pandemic, still our I our and Shifting shared backlog maintaining will than purpose on X% the such impact the a this to of I to than as more our Choice are of sabbaticals positive less For us minimize actions, profile. strong for employees, through financial be of while sought proud our EBITDA work, growth are our including continuity sum, suggest These prosecution program. Xx voluntary as instance, margin cost-mitigation deliver work we our conversations coupled client or part-time with actions that deterioration measures large our set before call colleagues, many continued more as we taking of our commitment the virtual our business now preventing backlog, on from our were as as well we in and couldn’t to earnings whose last targeted continue. unwavering. mission to COVID-XX strength, allowed supporting
are begun we to this more programs new schedules. While grown X,XXX as deploy recruiting staff than more these PPD we continue than have actions of work monitor we actually XX,XXX positions. colleagues. wind some mitigating down to from pandemic base and returning reduced with during has needed, employment our to actively And
our We is service our a are positioned of business. book clinical to This optimism in for well of trial signal conduct. record a recovery continued clear
we share to COVID-XX have position established a proud work. am leadership in I Finally, that
of clinical QX over the shared has phases as XX spectrum that from vaccines and it awards programs awards awards. as now most this represents The the our encompasses non-interventional call, I X enterprise, we report work excited I many too, can grown it On full-service early had spans this treatment about breadth to and biotech I am clients, XX Phase won awards, today. with agencies. XX government both to and of large development more of unique these programs, biopharma, applies to to than including studies. And
or a role is study PPD planned regardless Our significant of the with many labs whether studies and also accelerated running are playing enrollment the not. CRO solutions
are innovative these support it to to we sites, data Lastly, to patients whether capabilities our studies, of be direct-to-patient all applying capabilities remotely. patients network our to or enroll select our site solutions quickly
signals energized for by year our all, PPD’s challenging a us come life-changing to how I be respond medicines our to our The been to industry has by future. to need can stakeholders. mission across I this has collaborate see the am for innovative in been together While industry and of the by inspired more continue impressed day to every few organization clear. a the never and deliver I has continue how therapies. colleagues genuinely pandemic positive
front, to be budgets On and R&D continue customer the is funding biotech strong. robust,
a model both biotech and for access now and position. XX% operations. on willing we to they us continues And that than PPD even puts participate in We increasingly patient patients good access patients in leadership clinical survey seeing is access reported further CROs. sites note, to are to in to better. globally, proven sites of resumed a Site improve, strengthen patient Our of XX% normal our more More related position a have have than recent trials.
resilience We business. our have of site view through network a unique recruitment patient patient and
This we As emerge I the We even to normalcy of feel positive is the QX solid leading step forward broader for this nearly in is to development to industry from pharmaceutical of will clinical their and patients enrollment clinical pandemic. trial. a consents. participate patient in whereby the a willingness that step a believe confident trials. patient declare stronger past week, this a volumes return are to indicator back
believe culture talent execution will that industry-leading continue our For success. enable and PPD, our in particular, our of I to quality
the toward future, accelerating. the but high-level not with close I’ll business deteriorating, business. our Looking rather is view of my
win achieving continue commercial to front, with we customers, growth. backlog the our On double-digit
converting strongly adapted done discussed, emerge strong On the the we grip. pandemic our we’ve with the imagined. as more than have that I job operational we to from front, have Even the a pandemic’s we from could backlog revenue impacts
a with we I presents challenges able we second our guidance work a COVID review catch Operating turn prior adapt. work performance. us, operating We quarter Bill initiate our profile in margin results. I expect over to will from maintained on projections lastly, Sharbaugh, confident will as that we new be now to further up our and to Officer, year line to paused Whatever And on feel perspective, it Chief and accelerate awards. financial outpaced
